

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

### NICE Technology Appraisal No.367; Vortioxetine for treating major depressive disorder

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> <li>• Lundbeck (vortioxetine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• C.A.L.M.</li> <li>• Charlie Waller Memorial Trust</li> <li>• Chinese Mental Health Association</li> <li>• Combat Stress</li> <li>• Depression UK</li> <li>• Making Space</li> <li>• Mental Health Foundation</li> <li>• Mental Health Matters</li> <li>• MIND</li> <li>• Muslim Council of Britain</li> <li>• Race Equality Foundation</li> <li>• Rethink</li> <li>• SANE</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Matthew Trust</li> <li>• Together</li> <li>• United Response</li> <li>• WISH - A Voice for women's mental health</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Counselling and Psychotherapy</li> <li>• British Association for Psychopharmacology</li> <li>• British Association of Behavioural and Cognitive Psychotherapies</li> <li>• British Association of Occupational Therapists and College of Occupational Therapists</li> <li>• British Association of Psychotherapists</li> <li>• British Association of Social Workers</li> <li>• British Psychoanalytic Council</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• Care Council for Wales</li> <li>• Hafal</li> <li>• MIND Cymru</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Social Care Institute for Excellence</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine)</li> <li>• Amneal Pharma Europe (duloxetine, paroxetine)</li> <li>• Arristo Pharma (quetiapine)</li> <li>• AstraZeneca (quetiapine)</li> <li>• Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline and venlafaxine)</li> </ul>

<ul style="list-style-type: none"> <li>• British Neuropsychiatry Association</li> <li>• British Psychological Society</li> <li>• British Geriatrics Society</li> <li>• Royal College of General Practitioners</li> <li>• Clifford Beers Foundation</li> <li>• College of Mental Health Pharmacy</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Counsellors and Psychotherapists in Primary Care</li> <li>• Royal College of Physicians</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• Health and Care Professions Council</li> <li>• Mental Health Nurses Association</li> <li>• Primary Care Mental Health Education</li> <li>• Royal College of Psychiatrists</li> <li>• Royal Pharmaceutical Society</li> <li>• UK Council for Psychotherapy</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Welsh Government</li> <li>• NHS Hardwick CCG</li> <li>• NHS Norwich CCG</li> </ul>	<ul style="list-style-type: none"> <li>• Chiesi (venlafaxine)</li> <li>• Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine)</li> <li>• Creo Pharma (lofepramine and trazodone)</li> <li>• Dexcel Pharma (venlafaxine)</li> <li>• Dr Reddys Labs (duloxetine, fluoxetine and sertraline)</li> <li>• Fontus health (quetiapine)</li> <li>• GlaxoSmithKline (paroxetine)</li> <li>• HBS Healthcare (duloxetine)</li> <li>• Janssen (esketamine)</li> <li>• King Pharmaceuticals (nortriptyline)</li> <li>• Kyowa Kirin (phenelzine)</li> <li>• Lilly UK (duloxetine and fluoxetine)</li> <li>• Lundbeck (citalopram, escitalopram)</li> <li>• Lupin (sertraline)</li> <li>• Marlborough (doxepin)</li> <li>• Merck Sharp &amp; Dohme (mirtazapine)</li> <li>• Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine)</li> <li>• Par Laboratories Europe (fluoxetine)</li> <li>• Pfizer (reboxetine, sertraline and venlafaxine)</li> <li>• Rivopharm (citalopram, trazodone)</li> <li>• Sandoz (citalopram, paroxetine and quetiapine)</li> <li>• Servier (agomelatine)</li> <li>• Sun Pharmaceuticals (sertraline and venlafaxine)</li> <li>• Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine)</li> <li>• Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine)</li> <li>• Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Campbell Collaboration Social Welfare Group</li> <li>• Careif</li> </ul>
--	--

## APPENDIX A

	<ul style="list-style-type: none"><li>• Cochrane Depression Anxiety and Neurosis Group</li><li>• Health Services Research Unit, Department of Public Health, University of Oxford</li><li>• Institute of Psychiatry</li><li>• Joseph Rowntree Foundation</li><li>• National Primary Care Research &amp; Development Centre</li><li>• MRC Clinical Trials Unit</li><li>• National Institute for Health Research</li></ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"><li>• Public Health England</li><li>• Public Health Wales</li></ul>
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.